Janet Wale1, Anna Mae Scott2, Bjørn Hofmann3, Sarah Garner4, Eric Low5, Lloyd Sansom6. 1. Health Technology Assessment International (HTAi) Patient and Citizen Involvement in HTA Interest Groupsocrates111@bigpond.com. 2. Centre for Research in Evidence-Based Practice. 3. Department for Health Sciences,Norwegian University of Science and Technology;Centre for Medical Ethics,University of Oslo. 4. National Institute for Health and Care Excellence. 5. MyelomaUK. 6. Division of Health Sciences,University of South Australia.
Abstract
OBJECTIVES: Some countries make considerable effort to involve patients and patient groups in their health technology assessment (HTA) processes; others are only just considering or are yet to consider patient involvement in HTA. METHODS: This commentary offers four arguments why patient involvement should be prioritized by those HTA agencies that do not yet involve patients: (1) from a patients' rights perspective, (2) based on patient and community values, (3) centering on evidentiary contributions, and (4) from a methodological perspective. RESULTS: The first argument builds on the Alma-Ata Declaration, which holds that patients have a right and duty to have a say in the planning and delivery of their health care, individually and collectively. Where HTA is used to determine access to technologies and services, we argue that patients have a right to be heard. The second argues that decisions about treatments and services need to be aligned with the core values and morals of the patients whom the health system serves. The third argues that patients have unique knowledge and insights about living with a health condition and their needs for services and treatments regarding that condition, which can add to the knowledge base and value of the HTA process. The fourth argues that involvement of patients can facilitate methodological advancement of HTA, in areas such as early scientific advice and managed entry with evidence development. CONCLUSIONS: An HTA process that includes patient perspectives can, therefore, provide added value to patients, policy makers and healthcare professionals alike.
OBJECTIVES: Some countries make considerable effort to involve patients and patient groups in their health technology assessment (HTA) processes; others are only just considering or are yet to consider patient involvement in HTA. METHODS: This commentary offers four arguments why patient involvement should be prioritized by those HTA agencies that do not yet involve patients: (1) from a patients' rights perspective, (2) based on patient and community values, (3) centering on evidentiary contributions, and (4) from a methodological perspective. RESULTS: The first argument builds on the Alma-Ata Declaration, which holds that patients have a right and duty to have a say in the planning and delivery of their health care, individually and collectively. Where HTA is used to determine access to technologies and services, we argue that patients have a right to be heard. The second argues that decisions about treatments and services need to be aligned with the core values and morals of the patients whom the health system serves. The third argues that patients have unique knowledge and insights about living with a health condition and their needs for services and treatments regarding that condition, which can add to the knowledge base and value of the HTA process. The fourth argues that involvement of patients can facilitate methodological advancement of HTA, in areas such as early scientific advice and managed entry with evidence development. CONCLUSIONS: An HTA process that includes patient perspectives can, therefore, provide added value to patients, policy makers and healthcare professionals alike.
Authors: Amy Hunter; Karen Facey; Victoria Thomas; David Haerry; Kay Warner; Ingrid Klingmann; Matthew May; Wolf See Journal: Front Med (Lausanne) Date: 2018-09-06
Authors: Janet L Wale; David Chandler; Deborah Collyar; Dominique Hamerlijnck; Roberto Saldana; Zack Pemberton-Whitely Journal: Front Med Technol Date: 2022-01-25
Authors: Maria Dimitrova; Ivett Jakab; Zornitsa Mitkova; Maria Kamusheva; Konstantin Tachkov; Bertalan Nemeth; Antal Zemplenyi; Dalia Dawoud; Diana M J Delnoij; François Houýez; Zoltan Kalo Journal: Front Public Health Date: 2022-07-28
Authors: Roland E Schmieder; David E Kandzari; Tzung-Dau Wang; Ying-Hsiang Lee; Gabriel Lazarus; Atul Pathak Journal: J Hypertens Date: 2021-01 Impact factor: 4.776